• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings.

    "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage."

    "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our commercial growth."

    As Managing Director of BioGenerator Ventures, Winkeler led investments, sat on portfolio company boards of directors, and built new companies. She managed investments including Panome Bio, a private-equity-backed multi-omics startup, RevivBio, leveraging protein engineering and advanced microfluidics for applications in agriculture and other industries, and Pairidex, using novel droplet digital PCR technology to improve cancer outcomes.

    "Crystal possesses a rare combination of scientific depth with the ability to build meaningful business relationships," said Edward Weinstein, CEO of Panome Bio. "Her talents have been instrumental to the success of multiple startups."

    Prior to BioGenerator Ventures, Winkeler was Chief Operating Officer and Vice President of R&D of Canopy Biosciences, acquired by Bruker (NASDAQ:BRKR), where it now operates as Bruker Spatial Biology. Winkeler co-founded Canopy Biosciences and was instrumental in the growth of the company, including multiple PE-backed acquisitions. She led efforts in fundraising, technology sourcing and licensing, commercialization, operations, and business development. At the time that she left Bruker, Winkeler led an international team of over 40 people across sites in St. Louis, Leipzig and Hannover in Germany, and the Bay Area.

    "As Canopy's Board Chairman, I witnessed Crystal's leadership of the Canopy team through critical product launches and business development milestones," said Frank Witney, Operating Partner at Ampersand Capital Partners.

    Prior to Canopy, Winkeler spent four years at BioGenerator Ventures where she led due diligence for seed investments in companies such as Benson Hill, CoverCress, and Confluence Life Sciences.

    Winkeler completed a Ph.D. in Molecular Cell Biology at Washington University.

    Solis has demonstrated significant traction across start-ups to large multinational agriculture companies, recruited and grown a team of industry-experienced scientists, and launched product offerings in plant transformation and gene editing. The company expanded its management team, secured a license to the Pairwise Fulcrum™ Platform, entered the whole-genome-sequencing space through the acquisition of Ferris Genomics, secured new investment from Cultivation Capital, and dramatically increased sales.

    Solis' major investors are Hermann Companies, Cultivation Capital, Jim McKelvey's Saloniki Investments, BioGenerator Ventures, and QRM Capital. Additional investors include St. Louis Arch Angels, Missouri Technology Corporation, Helix Fund, CIG Spectrum, Hypha Life Sciences, and various angel investors.

    About Solis Agrosciences

    Solis Agrosciences is the trusted partner for high-quality AgTech research services. We generate gene-edited and transgenic crops, plant phenotype and efficacy data, end-to-end genomics sequencing services, and individually tailored research solutions for our startup and corporate customers. Solis' highly trained and industry-experienced scientists operate in the 39 North AgTech Innovation District of St. Louis, Missouri. Visit solisagrosciences.com to learn more.

    About Cultivation Capital

    Cultivation Capital is an early-stage venture capital firm investing in software technology, life sciences, agriculture technology, and geospatial technology companies. Since its founding in 2012, the firm has invested in over 150 companies and is recognized as one of the most active early-stage investors in the United States. For more information, visit cultivationcapital.com

    About Hermann Companies

    Founded in 1956, Hermann Companies combines three generations of experience to make investments across a spectrum of asset classes and industries. Hermann offers a variety of capital solutions to accomplish its goal of partnering with strong, entrepreneurial teams through meaningful direct investments. Visit hermcos.com to learn more.

    39 North AgTech Innovation District, St. Louis, Missouri is a vibrant innovation district cultivating the infrastructure, talent, and access to capital to facilitate agrifood tech innovation and to advance ideas from lab to market. Visit 39northstl.org to learn more.

    CONTACT

    [email protected]



    Primary Logo

    Get the next $BRKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/10/2025$60.00Peer Perform → Outperform
    Wolfe Research
    12/9/2025$40.00Sell
    Goldman
    11/20/2025$60.00Buy
    Rothschild & Co Redburn
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    More analyst ratings

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00

    12/10/25 9:02:11 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Bruker with a new price target

    Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00

    12/9/25 8:43:14 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Bruker with a new price target

    Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00

    11/20/25 8:06:38 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

    The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (NASDAQ:BRKR), today announced two multi-year supply agreements for Bruker's latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109007299/en/Typical niobium-titanium-copper composite superconductors suitable for MRI magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration periods, with one agreement ex

    1/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

    TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker

    1/8/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

    Bruker Corporation (NASDAQ:BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Br

    1/7/26 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Phillips Jack

    3 - BRUKER CORP (0001109354) (Issuer)

    1/9/26 6:19:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 33,843 shares at a strike of $22.19 and sold $1,680,647 worth of shares (33,843 units at $49.66) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/6/26 4:15:20 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Packer Richard A exercised 10,000 shares at a strike of $24.00 and sold $243,230 worth of shares (5,028 units at $48.38), increasing direct ownership by 6% to 89,174 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    12/2/25 4:15:07 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    12/9/25 10:10:52 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Bruker Corporation

    144 - BRUKER CORP (0001109354) (Subject)

    12/1/25 4:14:06 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SCHEDULE 13G filed by Bruker Corporation

    SCHEDULE 13G - BRUKER CORP (0001109354) (Subject)

    11/14/25 12:53:25 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

    TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker

    1/8/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend

    Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock, par value $0.01 per share (the "Common Stock Dividend"). The Common Stock Dividend will be paid on January 2, 2026 to stockholders of record as of December 8, 2025. The Board also approved payment of a quarterly cash dividend in the amount of $3.6745 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on Decemb

    11/4/25 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Reports Third Quarter 2025 Financial Results

    Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted earnings per share (EPS) $0.45 Updated FY2025 guidance: Revenue $3.41 to $3.44 billion; reported growth of 1-2% yoy, organic decline of 4-5% Non-GAAP EPS $1.85 to $1.90   Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three and nine months ended September 30, 2025. Frank H. Laukien, Bruker's President and CEO, commented: "In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio

    11/3/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials